Dr. Stephanie Eileen McLaughlin, MD

Dr. McLaughlin practices at Harborview Medical Center in Seattle, Washington, part of University of Washington.

Dr. McLaughlin's NPI, 1629318092, was assigned on February 22, 2013. Dr. McLaughlin graduated from Johns Hopkins University School of Medicine in 2016. Dr. McLaughlin holds Washington license 60950336.

Dr. McLaughlin's primary practice is Harborview Medical Center, at 325 9th Avenue, Seattle, WA 98104 in King County. The practice phone is (206) 744-9535.

Dr. McLaughlin's primary practice is Harborview Medical Center in Seattle, Washington, part of University of Washington. Dr. McLaughlin is also affiliated with UW Medical Center - Montlake. The medical group on file is UW Physicians. Dmand AI also links Dr. McLaughlin to 1 more hospital, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. McLaughlin practices, 3 sites in all. Vendor and product names are available with a free account.

Infectious disease is Dr. McLaughlin's primary specialty in the NPI Registry, under taxonomy code 207RI0200X. Dr. McLaughlin is licensed in Washington.

CMS data shows 17 Medicare services from Dr. McLaughlin across 1 procedure code in 2024, for 41 Medicare patients. Medicare paid $2,598 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 41 Medicare patients who saw Dr. McLaughlin in 2024. The largest group is 65 to 74, with 17 patients. 75% of them have high blood pressure, and 63% have high cholesterol. 41% are also on Medicaid. Their average risk score is 2.75, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. McLaughlin's median patient age at 61, with 41% women.

In 2024, Dr. McLaughlin wrote 756 Medicare Part D claims for 30 patients. 58% of them were for generic drugs. CMS names the drug for 530 of them, across 17 drugs with 11 or more claims each, at $726,654 in total drug cost. In 2023, CMS named 400 claims across 15 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. McLaughlin for performance year 2024, reported through an alternative payment model (APM). Dr. McLaughlin accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 9 papers to Dr. McLaughlin, published from 2012 to 2025. 2021 was the busiest year, with 2. The most frequent topics are Gonorrhea, Neisseria gonorrhoeae and Cervix Uteri. Dr. McLaughlin has published most often in Sex Transm Dis. Dr. McLaughlin's most frequent co-authors are Khalil G. Ghanem, MD, Matthew Robert Golden, MD and John Mcleod Griffiss, MD.

Dr. McLaughlin graduated from Johns Hopkins University School of Medicine in 2016.